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Abstract We here report that after infection with human her-
pesvirus 6A, human cord blood mononuclear cells accumulate in
G2/M phase of the cell cycle. Experiments with foscarnet or
ultraviolet (UV)-irradiated virus stocks pointed at an (immedi-
ate-)early, newly formed viral protein to be responsible for the
arrest. At the molecular level, p53, cyclin B1, cyclin A and
tyrosine15-phosphorylated cdk1 accumulated after HHV-6A in-
fection, indicating an arrest in G2. However, no change was
observed in the levels of downstream e¡ectors of p53 in estab-
lishing a G2 arrest, i.e. p21 and 14-3-3c. We thus conclude that
the HHV-6A-induced G2 arrest occurs independently of p53
accumulation.
. 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
HHV-6 (human herpesvirus 6) primary infection is the
cause of exanthema subitum in young children [1]. This highly
seroprevalent virus may reactivate during episodes of immune
suppression (e.g. in transplant recipients or AIDS patients)
causing disseminated infection of various organs [2]. Although
HHV-6 has tentatively been linked to certain lymphoprolifer-
ative disorders, its oncogenic potential has not been estab-
lished. Indeed, the ubiquitous nature of the pathogen, and
its ability to remain in a latent state and to integrate into
the host cell chromosomal DNA [3], complicate the interpre-
tation of polymerase chain reaction (PCR) analysis on tumor
tissue [4]. As a betaherpesvirus, HHV-6 (which exists as two
variants, A and B) is closely related to HHV-7 and, more
distantly, human cytomegalovirus (HCMV). HHV-6 has a
broad in vivo cell tropism, but in vitro replication occurs
most e⁄ciently in T-lymphocytes and neural cells. Several
e¡ects of HHV-6 infection on host cell metabolism have
been described, such as modulation of the host cell’s immune
responses (reviewed in [5]), shuto¡ of cellular DNA synthesis
[6] and stimulation of the host cell protein synthesis [7]. More-
over, HHV-6 is capable of inducing apoptosis both in contin-
uous cell lines and in cord blood mononuclear cells (CBMCs)
[8^10], and the protein encoded by the HHV-6 DR7 gene was
shown to bind to p53 and to inhibit p53-activated transcrip-
tion [11]. It was speculated by Braun et al. [12] that the virus
might disrupt a component of the cell cycle that links cyto-
plasmic growth with cell division. The present report is the
¢rst detailed investigation into the e¡ects of HHV-6 infection
on cell cycling and underlying events.
2. Materials and methods
2.1. Cells and virus
Human CBMCs were isolated by density gradient centrifugation
and cultured in RPMI medium supplemented with 10% fetal calf
serum (FCS) (both from Life Technologies), 10 Wg/ml phytohemag-
glutinin A and 10 U/ml interleukin-2 (IL-2) for 48 h (both from
Roche). Cell-free virus preparations of HHV-6A (strain GS) and
HHV-6B (strain Z29) were prepared as described before [13]. Titers
were determined as viral DNA equivalents by quantitative PCR and
con¢rmed by endpoint dilution of viral inocula on cell cultures. A
multiplicity of infection of 10 virus particles per cell was used
throughout our experiments. 24 h prior to infection, cells were trans-
ferred to a low-mitogen regimen (RPMI medium containing 10% FCS
and 2 U/ml IL-2) at a density of 5U105 cells/ml.
2.2. Cell cycle analysis
Custom cell cycle analysis was performed on 106 cell nuclei at
di¡erent time points post infection (p.i.) using the Cycle Test Plus
DNA Reagent Kit (BD Biosciences) according to the manufacturer’s
instructions. Cell doublets were excluded from the £uorescence-acti-
vated cell sorter (FACS) analysis by conventional dot plot gating.
Simultaneous staining of HHV-6 antigen and cellular DNA was per-
formed as follows: 106 cells were ¢xed in 70% ethanol for 30 min at
4‡C. After several washes with phosphate-bu¡ered saline (PBS), cells
were stained with a polyclonal antibody raised against the pU69 pro-
tein of HHV-6 [13] and subsequently with £uorescein isothiocyanate
(FITC)-conjugated anti-rabbit IgG antibody (Dako). Cells were then
treated with 0.1% Triton X-100 (Sigma), 20 Wg/ml RNase A (Boehr-
inger Mannheim) and stained with 10 Wg/ml propidium iodide (Sigma)
for 10 min, prior to FACS analysis.
2.3. Western blot analysis
Total protein from 2.5U106 CBMCs was extracted at di¡erent time
points after HHV-6 infection and subjected to sodium dodecyl sul-
fate^polyacrylamide gel electrophoresis (SDS^PAGE) on 12% Tris^
HCl gels (pH 8.8), electroblotting and antibody binding, as described
previously [13]. Mouse monoclonal antibodies to cdk1, proliferating
cell nuclear antigen (PCNA), p21waf1, cyclin D1 and p53 (from Cal-
biochem), cdk2, cdc25C, cyclin B1, phospho-Tyr15-cdk1 and phospho-
Ser216-cdc25C (from Santa Cruz Biotechnology), and cyclins A and E
(both from Pharmingen) were diluted to 0.1^0.5 Wg/ml. The rabbit
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polyclonal antisera raised against the HHV-6 proteins pU90 (kind gift
of Dr. Y. Inoue) and pU69 [13] were diluted 1/500. Detection of the
horseradish peroxidase-labeled immune complexes was performed us-
ing the chemiluminescence ECL Plus detection system (Amersham).
2.4. Immuno£uorescence analysis
Aliquots of 5U104 cells were spotted onto glass slides and allowed
to dry prior to ¢xation in ice-cold methanol for 5 min. For FACS
analysis, 5U105 cells were washed with PBS and ¢xed with 4% form-
aldehyde for 10 min at 4‡C. Simultaneous detection of viral and
cellular proteins was carried out by overnight incubation at 4‡C
with primary antibody from di¡erent species. Secondary FITC-and
tetrarhodamine isothiocyanate (TRITC)-labeled antibodies were
added for 45 min at 37‡C. Antibodies were diluted in PBS containing
1% FCS and 0.1% Tween 20. Slide preparations were ¢nally mounted
in Vectashield medium (Vector Laboratories). Samples for £ow cyto-
metry were ¢xed in 1% formaldehyde in PBS and analyzed on a
FACScan £ow cytometer (BD Biosciences). As a negative control
for non-speci¢c background staining, cells were stained in parallel
with secondary antibody alone.
3. Results and discussion
3.1. Interference of HHV-6 with cell cycle progression
To investigate the in£uence of HHV-6 infection on cell
cycle progression, we investigated the DNA content of
CBMCs after infection with HHV-6 at high multiplicity of
infection (MOI) (10 viral particles per cell). Similar to the
observation made by Secchiero et al. for HHV-7 [14], a
marked accumulation of cells in G2/M phase of the cell cycle
was observed in HHV-6-infected vs. mock-infected cells from
12 h p.i. onwards (Fig. 1). This e¡ect increased over time up
to 48 h p.i. (cell viability at later time points declined due to
cytopathic e¡ects (CPEs)) and was most pronounced after
HHV-6A infection (34.5% cells in G2/M phase vs. 10.2% in
the mock-infected condition). The proportion of cells in S
phase remained constant at about 20% of the population until
72 h p.i., when it dropped to 8% in the mock-infected con-
ditions, but remained unchanged in infected conditions. When
DNA content and HHV-6 pU69 antigen expression were de-
termined simultaneously by FACS analysis, pU69-positive
cells appeared in both the 2n and 4n populations (Fig. 4,
upper panel). Nevertheless, the distribution of pU69-positive
cells was more pronounced towards G2/M arrest (55% vs. 34%
for the whole population of HHV-6-infected cells). In parallel
with cell cycle analysis, cell numbers were determined; mock-
infected cells had doubled by 48 h p.i. and undergone two
rounds of replication after 96 h, whereas in HHV-6A-infected
cells no increase in cell number was observed over time,
strong CPE was visible as from 48 h p.i. and cell viability
was 50% after 72 h. Cells infected with HHV-6B showed an
intermediate growth pattern and minor CPE (data not
shown). The viral immediate-early pU90 and early pU69 anti-
gens were quanti¢ed by Western blot (Fig. 3) to ensure that
equal multiplicities of infection were used for both A and B
variants. However, since di¡erences in replication e⁄ciency
Fig. 1. HHV-6 infection induces G2/M phase arrest. At di¡erent time points after infection of human CBMCs, the relative DNA content was
determined by propidium iodide staining of cell nuclei and £ow cytometric analysis. Numbers given are the mean percentages (from three ex-
periments) of cells with a 4n DNA content. Debris and doublets were excluded from the analysis by conventional dot plot gating. Histograms
shown are from one experiment, representative of three independent experiments.
Fig. 2. E¡ect of foscarnet (0.5 mM) (A) and UV irradiation (B) on
the HHV-6A-induced G2/M arrest at 48 h p.i. Data shown are the
results ( T S.D.) from two independent experiments, each performed
in duplicate.
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between both variants have been described according to the
cell type used [15], and our HHV-6A and HHV-6B virus
stocks were passaged on di¡erent cell lines, the observed dif-
ferences in the cell cycle e¡ects of the A and B variants may
be di⁄cult to interpret.
To further characterize the observed e¡ect of HHV-6A in-
fection on the cell cycle, mock- and HHV-6A-infected
CBMCs were treated with 0.5 mM foscarnet upon infection
and cell cycle analysis was performed at 48 h (Fig. 2A), 72 h
and 96 h p.i. (not shown). No di¡erences in cell cycle distri-
bution were observed between foscarnet-treated and untreated
cells, neither in mock- nor in HHV-6A-infected conditions. In
spite of the inhibition of viral replication by foscarnet (as
ascertained by the absence of viral DNA and protein at 96
h p.i. (data not shown)), the foscarnet-treated HHV-6A-in-
fected cells accumulated in G2/M. This points at an immedi-
ate-early or early event in the viral replication cycle to be
responsible for the cell cycle arrest, as late protein synthesis
is virtually abolished by high-dose foscarnet. In order to de-
termine whether the HHV-6-induced G2/M arrest requires vi-
rus replication, the HHV-6A stock was ultraviolet (UV)-irra-
diated for 20 min. This treatment reduced virus infectivity by
s 95% as determined by infection of Sup-T1 lymphoblastoma
cells and quantitation of viral protein at 4 days p.i. (data not
shown). UV irradiation eliminated the virus’ capacity of in-
ducing a G2/M arrest (Fig. 2B), indicating that de novo viral
protein synthesis is a prerequisite for the virus-induced cell
cycle arrest to occur. Events at the level of HHV-6 binding
and entry, or proteins present in the tegument of the virus
particle apparently do not exert important e¡ects here ^ in
contrast to the HCMV-induced arrest at the G1/S boundary in
which the tegument proteins pUL69 and pp71 actively partic-
ipate [16]. Mitogenic stimulation of CBMCs is a prerequisite
for their infection by HHV-6 [17]. However, to investigate
whether HHV-6, like HCMV, can force cells to enter the
cell cycle (i.e. pass the G0/G1 transition) prior to arresting
them, we performed an experiment in which no mitogens
were added to freshly isolated CBMCs, and HHV-6A was
added immediately upon isolation. Cell cycle analysis, per-
formed as described above at 6 h intervals between 0 and
30 h p.i., revealed that s 95% of both the mock-infected
and HHV-6A-infected cell populations had a DNA content
corresponding to the G1 (or G0) phase and, hence, no mea-
surable induction of the cell cycle was observed (data not
shown).
3.2. E¡ect of HHV-6 infection on selected cell cycle protein
expression levels
In order to characterize the underlying molecular events
involved in the described G2/M arrest, the steady-state protein
levels of several key players in cell cycle regulation were de-
termined by Western blotting (Fig. 3). A manifest accumula-
tion of cyclins A and B1, involved in S phase and G2/M
transition, was observed in HHV-6A-infected conditions
from 12^24 h p.i. onwards. The fact that cyclin B1, although
clearly upregulated in the HHV-6A-infected condition, does
not localize to the same cells as HHV-6 pU69 (Fig. 5, panel
2), does not exclude a role for HHV-6 in cyclin B1 accumu-
lation, as pU69 most likely is not involved and may show a
di¡erent temporal expression pattern. Moreover, the cytoplas-
mic localization of cyclin B1 after HHV-6A infection suggests
a G2 arrest, rather than an arrest in mitosis, when cyclin B1 is
present in the nucleus. A less pronounced accumulation of
cyclin B steady-state levels was also reported after HHV-7
infection (albeit at later time points) [14]. However, whereas
after HHV-7 infection, cyclin B expression was reported to be
unscheduled, cyclin B1 upregulation after HHV-6A infection
was con¢ned to cells with a DNA content of 4n (Fig. 4, lower
panel). Neither did we observe an accumulation of total cdk1
(as reported for HHV-7), although a signi¢cant increase of its
Tyr15-phosphorylated form became apparent from 24 h p.i.
onwards, in parallel with cyclin B1 levels. This agrees entirely
Fig. 3. Western blot analysis of steady-state levels of a panel of pro-
teins involved in cell cycle control. Human CBMCs were infected
with HHV-6A (A) or HHV-6B (B) or mock infected (3). At di¡er-
ent time points after infection, protein extracts were prepared and
10 Wg of total protein was analyzed by SDS^PAGE, electroblotting
and enhanced chemiluminescence detection.
Fig. 4. Scatter plot analysis of uninfected (left) and HHV-6-infected
(right) CBMCs at 48 h p.i. Cells were stained simultaneously for
HHV-6 pU69 antigen (upper panel) or cyclin B1 (lower panel) ex-
pression and for DNA content as described in Section 2. Cells
showing high antigen expression are marked by arrows.
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with our data on the altered cell cycle distribution after HHV-
6A infection, and points to a maintained G2 arrest, as dephos-
phorylation of the tyrosine residue at position 15 of cdk1 is a
prerequisite for entry into mitosis [18]. Cyclin E, which peaks
at G1/S transition, was slightly augmented at 24 h p.i. in the
HHV-6A-infected condition, but this e¡ect was not main-
tained at later time points. These ¢ndings contrast with the
HCMV-induced G2/M arrest in cycling cells, where induction
of high levels of cyclin E was reported and cyclin A appeared
only at late time points [19].
We observed no HHV-6-induced alterations in the steady-
state levels of cyclin D1 (the G1-speci¢c cyclin) and cdk2,
although it should be noted that protein expression levels
do not necessarily correlate with activity levels. Furthermore,
HHV-6 infection did not alter the expression of PCNA and of
cdc25C ^ both the total cdc25C protein and its Ser216-phos-
phorylated form, which occurs after Chk-1/2-induced phos-
phorylation in response to e.g. DNA damage [18]. Both
PCNA and cdc25C are involved in the G2/M checkpoint
through speci¢c interactions with each other, p21 and the
cdk1/cyclin B complex [20,21].
The protein most manifestly a¡ected by HHV-6A infection
was the tumor suppressor protein p53, an important e¡ector
molecule that acts in multiple ways: it is capable of inducing a
cell cycle arrest both in G1 phase and at the entry into mitosis
(DNA damage checkpoint) [18]. On the other hand, p53 is
capable of inducing apoptosis if cellular DNA is damaged
beyond repair [22]. A strong accumulation of p53 has also
been observed following expression of the herpes simplex vi-
rus (HSV)-1 ICP0 protein [23] and after HCMV [19,24,25]
infection. Moreover, the protein encoded by the HHV-6 im-
mediate-early DR7 gene (pDR7) was shown to bind and sta-
bilize p53, and to repress its transcriptional activities [11]. Our
observations support this ¢nding. Indeed, the accumulation of
p53 after HHV-6 infection was the earliest detectable event,
initiating as soon as 2 h p.i. (Fig. 3). Moreover, p53-positive
cells are strongly positive for HHV-6A pU69 (Fig. 5, panel 1).
However, if the accumulation of p53 would correlate with an
enhanced activity, one would expect p21 and 14-3-3c to be
induced and cdk1 and cyclin B1 levels to decline ^ since their
transcription is regulated by p53 [18]. This was clearly not the
case in our experiments. One could thus assume that the ac-
cumulated p53 is inactive as a transcription factor, e.g.
through binding of pDR7 or through alteration of its cellular
distribution, since active p53 is located in the nucleus [26]. In
HHV-6A-infected cells, p53 seems present in the cytoplasm
(Fig. 5, panel 1d). A similar observation was made after
HCMV infection [27,28], although sequestration of p53 in
viral replication centers in the nucleus has also been reported
[29]. On the other hand, the observed p53 induction correlates
with the emerging apoptotic fraction (cells with a hypodiploid
DNA content) in HHV-6A- and HHV-6B-infected conditions
from 24 h p.i. onwards (Fig. 1). Whereas the hypodiploid
fraction in mock-infected CBMCs remained below 2%, it in-
creased to 3.6, 10.9 and 21.7% after HHV-6A infection at 24,
48 and 72 h, respectively. Apoptosis, the second major out-
come of p53 induction, may occur independently of the tran-
scriptional activities of p53 [22] and has been reported to be
induced by HHV-6 infection, although the underlying mech-
anisms are not yet fully understood [8^10]. In summary, based
on the observations that steady-state levels of p21, 14-3-3c
and Ser216-phosphorylated cdc25C remain una¡ected after
HHV-6A infection, whereas cyclin B1, Tyr15-cdc2 and p53
accumulate, we conclude that mechanisms other than p53 or
Chk-1 activation, and possibly implying virally encoded fac-
tors, may be responsible for the observed G2 arrest.
3.3. Conclusion
The data presented here show that the cell cycle distribution
shifts towards cells with a 4n DNA content after HHV-6A
infection of CBMCs, as has been described for HHV-7-in-
fected CD4þ T-lymphocytes and Sup-T1 cells [14]. It remains
to be demonstrated, however, whether the underlying e¡ectors
(other than cyclin B) are a¡ected in a similar way by these two
viruses. The e¡ects of HHV-6 (and HHV-7) on cell cycling are
quite di¡erent from those observed for the other herpesvi-
ruses, HSV-1 and HCMV, which can arrest the cell cycle at
multiple stages. In the case of HCMV infection, divergent
e¡ects were observed depending on the cell’s permissiveness
and synchronization status, and di¡erent viral proteins were
Fig. 5. Expression patterns of p53 and cyclin B1 in uninfected (a
and b) and HHV-6-infected (c and d) CBMCs at 48 h p.i. The
same ¢eld of cells was stained simultaneously for the HHV-6 pU69
antigen (red £uorescence) and either p53 (panel 1) or cyclin B1
(panel 2), both visualized as green £uorescence. Original magni¢ca-
tion: 400U.
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found to exert opposite e¡ects on cell cycling [16]. The main
outcome for both HSV-1 and HCMV is an arrest at the G1/S
transition, which is considered the optimal environment for
viral replication without competition with the cellular DNA
replication machinery. We found no evidence for HHV-6 to
induce such an arrest. Moreover, although HCMV has been
described to arrest cells in G2/M phase in well-de¢ned con-
ditions, the underlying molecular expression patterns are
clearly di¡erent from those observed for HHV-6A. This
may explain our observation that the cdk inhibitor roscovi-
tine, which is active against HSV-1 and HCMV [30], has no
activity against HHV-6 (L. De Bolle, unpublished data).
In conclusion, our data on the G2/M arrest induced by
HHV-6A warrant further investigation into the underlying
molecular events responsible for the altered expression of cer-
tain key players in the G2/M transition. This, together with
the identi¢cation of the individual HHV-6 proteins responsi-
ble for this cell cycle arrest, will increase our insight into the
CPEs of this herpesvirus.
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